CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Precision BioSciences, Inc. - DTIL CFD

1.3284
1.48%
0.0132
Low: 1.3284
High: 1.3683
Market Trading Hours* (UTC) Opens on Friday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0132
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.3484
Open* 1.3584
1-Year Change* 1.37%
Day's Range* 1.3284 - 1.3284
52 wk Range 1.11-9.64
Average Volume (10 days) 0.63217
Average Volume (3 months) 16.2691
Market Cap 164.219
P/E Ratio N/A
Shares Outstanding 110959000
Revenue 20.839
EPS -1.50149
Dividend (Yield %) N/A
Beta 1.49403
Next Earnings Date Mar 13, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 30, 2022 1.3484 0.0300 2.28% 1.3184 1.3683 1.2984
Nov 29, 2022 1.2984 -0.0699 -5.11% 1.3683 1.3883 1.2984
Nov 28, 2022 1.3484 -0.0399 -2.87% 1.3883 1.4183 1.3484
Nov 25, 2022 1.3883 0.0000 0.00% 1.3883 1.4483 1.3783
Nov 23, 2022 1.3983 -0.0400 -2.78% 1.4383 1.4782 1.3983
Nov 22, 2022 1.4682 0.0100 0.69% 1.4582 1.4882 1.4183
Nov 21, 2022 1.4682 -0.0500 -3.29% 1.5182 1.5182 1.4483
Nov 18, 2022 1.5282 -0.0099 -0.64% 1.5381 1.5581 1.5182
Nov 17, 2022 1.5482 0.0300 1.98% 1.5182 1.5981 1.5182
Nov 16, 2022 1.5681 0.1199 8.28% 1.4482 1.6880 1.4482
Nov 15, 2022 1.4682 0.0200 1.38% 1.4482 1.5482 1.4482
Nov 14, 2022 1.4483 -0.0099 -0.68% 1.4582 1.5382 1.4383
Nov 11, 2022 1.4483 0.0800 5.85% 1.3683 1.4882 1.3484
Nov 10, 2022 1.3783 0.0200 1.47% 1.3583 1.4283 1.3583
Nov 9, 2022 1.3184 0.0499 3.93% 1.2685 1.3883 1.2585
Nov 8, 2022 1.2685 0.0200 1.60% 1.2485 1.2984 1.2285
Nov 7, 2022 1.2385 -0.0399 -3.12% 1.2784 1.2784 1.2385
Nov 4, 2022 1.2800 -0.1200 -8.57% 1.4000 1.4000 1.2600
Nov 3, 2022 1.3600 0.0600 4.62% 1.3000 1.3700 1.3000
Nov 2, 2022 1.3500 -0.0300 -2.17% 1.3800 1.4200 1.3400

Precision BioSciences, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 7.015 6.484 10.883 22.238 24.285 115.529
Revenue 7.015 6.484 10.883 22.238 24.285 115.529
Total Operating Expense 15.843 28.458 58.795 109.442 134.113 148.946
Selling/General/Admin. Expenses, Total 6.168 8.016 13.673 27.026 36.052 39.693
Research & Development 9.102 19.119 43.363 78.23 90.62 107.664
Depreciation / Amortization 0.573 1.205 1.759 4.186 7.441 7.574
Unusual Expense (Income) 0 0.118 0 0 -5.985
Operating Income -8.828 -21.974 -47.912 -87.204 -109.828 -33.417
Interest Income (Expense), Net Non-Operating 0.57 0.872 1.875 -5.673 0.822 2.815
Other, Net 0.002 0
Net Income Before Taxes -8.256 -21.102 -46.037 -92.877 -109.006 -30.602
Net Income After Taxes -8.251 -21.102 -46.037 -92.877 -109.006 -30.602
Net Income Before Extra. Items -8.251 -21.102 -46.037 -92.877 -109.006 -30.602
Net Income -8.251 -21.102 -46.037 -92.877 -109.006 -30.602
Income Available to Common Excl. Extra. Items -8.251 -21.102 -46.037 -92.877 -109.006 -30.602
Income Available to Common Incl. Extra. Items -8.251 -21.102 -46.037 -92.877 -109.006 -30.602
Diluted Net Income -8.251 -21.102 -46.037 -92.877 -109.006 -30.602
Diluted Weighted Average Shares 49.029 49.029 49.029 41.9912 52.0317 58.6881
Diluted EPS Excluding Extraordinary Items -0.16829 -0.4304 -0.93897 -2.21182 -2.09499 -0.52143
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.16829 -0.42799 -0.93897 -2.21182 -2.09499 -0.62341
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 16.349 68.805 24.036 6.339 3.317
Revenue 16.349 68.805 24.036 6.339 3.317
Total Operating Expense 35.091 47.173 35.578 31.104 30.663
Selling/General/Admin. Expenses, Total 9.498 9.938 9.638 10.619 10.691
Research & Development 23.76 35.226 24.036 24.643 18.32
Depreciation / Amortization 1.833 2.009 1.904 1.827 1.652
Operating Income -18.742 21.632 -11.542 -24.765 -27.346
Interest Income (Expense), Net Non-Operating 0.053 0.024 0.263 2.475 -0.822
Net Income Before Taxes -18.689 21.656 -11.279 -22.29 -28.168
Net Income After Taxes -18.689 21.656 -11.279 -22.29 -28.168
Net Income Before Extra. Items -18.689 21.656 -11.279 -22.29 -28.168
Net Income -18.689 21.656 -11.279 -22.29 -28.168
Income Available to Common Excl. Extra. Items -18.689 21.656 -11.279 -22.29 -28.168
Income Available to Common Incl. Extra. Items -18.689 21.656 -11.279 -22.29 -28.168
Diluted Net Income -18.689 21.656 -11.279 -22.29 -28.168
Diluted Weighted Average Shares 56.625 59.8416 59.6577 60.6968 61.0318
Diluted EPS Excluding Extraordinary Items -0.33005 0.36189 -0.18906 -0.36724 -0.46153
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.33005 0.36189 -0.18906 -0.46584 -0.46153
Unusual Expense (Income) -5.985
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 94.402 64.331 115.675 193.672 105.564 161.754
Cash and Short Term Investments 93.423 62.802 103.193 180.886 89.798 143.663
Cash & Equivalents 93.423 62.802 103.193 180.886 89.798 143.663
Total Receivables, Net 0.386 0.022 1.027 0.965 10 0.488
Prepaid Expenses 0.593 1.437 8.913 9.497 5.762 17.434
Other Current Assets, Total 0 0.07 2.542 2.324 0.004 0.169
Total Assets 98.414 72.682 138.6 235.233 150.158 211.498
Property/Plant/Equipment, Total - Net 3.544 8.137 21.147 39.571 41.5 29.334
Property/Plant/Equipment, Total - Gross 5.436 11.33 26.631 50.22 60.578 53.248
Accumulated Depreciation, Total -1.892 -3.193 -5.484 -10.649 -19.078 -23.914
Intangibles, Net 0.281 0.09 1.466 1.432 1.373 2.048
Other Long Term Assets, Total 0.187 0.124 0.312 0.558 1.721 4.641
Total Current Liabilities 8.34 9.203 14.075 26.932 42.829 35.98
Accounts Payable 1.286 1.806 2.218 2.037 0.792 1.144
Accrued Expenses 0.635 1.483 3.053 8.409 10.947 12.615
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 6.419 5.914 8.804 16.486 31.09 22.221
Total Liabilities 103.163 99.051 98.64 96.919 105.733 120.33
Total Long Term Debt 0 0 0 0 0 2.478
Other Liabilities, Total 94.823 89.848 84.565 69.987 62.904 81.872
Total Equity -4.749 -26.369 39.96 138.314 44.425 91.168
Redeemable Preferred Stock 0.003 0.003 0.005 0
Additional Paid-In Capital 13.257 13.691 126.094 316.333 331.45 408.795
Retained Earnings (Accumulated Deficit) -18.009 -39.111 -85.187 -177.067 -286.073 -316.675
Treasury Stock - Common 0 -0.952 -0.952 -0.952 -0.952 -0.952
Total Liabilities & Shareholders’ Equity 98.414 72.682 138.6 235.233 150.158 211.498
Total Common Shares Outstanding 49.029 49.029 49.029 51.1552 52.6926 60.9021
Accounts Receivable - Trade, Net 0.523 0.965 10 0.488
Long Term Investments 6.842
Note Receivable - Long Term 6.879
Long Term Debt 2.478
Common Stock 0.00031
Other Equity, Total -0.00031
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 219.139 188.304 183.048 161.754 134.053
Cash and Short Term Investments 193.46 173.943 160.471 143.663 116.222
Cash & Equivalents 193.46 173.943 160.471 143.663 116.222
Total Receivables, Net 19.263 0.488 0.488 0.488 0.488
Accounts Receivable - Trade, Net 19.263 0.488 0.488 0.488 0.488
Prepaid Expenses 6.381 8.457 21.191 17.434 17.06
Other Current Assets, Total 0.035 5.416 0.898 0.169 0.283
Total Assets 262.316 230.114 227.199 211.498 181.351
Property/Plant/Equipment, Total - Net 40.007 38.602 37.049 29.334 27.766
Intangibles, Net 1.358 1.343 2.074 2.048 2.021
Other Long Term Assets, Total 1.812 1.865 4.216 4.641 4.655
Total Current Liabilities 63.797 36.251 36.475 35.98 29.106
Accounts Payable 0.445 0.478 0.486 1.144 0.699
Accrued Expenses 8.228 9.512 9.679 12.615 7.101
Notes Payable/Short Term Debt 0 2.431 2.454 0 0
Other Current Liabilities, Total 55.124 23.83 23.856 22.221 21.306
Total Liabilities 203.494 129.561 125.756 120.33 111.692
Total Long Term Debt 0 0 0 2.478 2.482
Other Liabilities, Total 139.697 93.31 89.281 81.872 80.104
Total Equity 58.822 100.553 101.443 91.168 69.659
Redeemable Preferred Stock 0
Additional Paid-In Capital 364.536 384.611 396.78 408.795 415.454
Retained Earnings (Accumulated Deficit) -304.762 -283.106 -294.385 -316.675 -344.843
Treasury Stock - Common -0.952 -0.952 -0.952 -0.952 -0.952
Total Liabilities & Shareholders’ Equity 262.316 230.114 227.199 211.498 181.351
Total Common Shares Outstanding 57.2224 59.283 60.0816 60.9021 61.7746
Long Term Investments 0.812 6.842 5.89
Common Stock 0.0003 0.00031 0.00031
Other Equity, Total -0.0003 -0.00031 -0.00031
Note Receivable - Long Term 6.879 6.966
Long Term Debt 2.478 2.482
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -8.251 -21.102 -46.037 -92.877 -109.006 -30.602
Cash From Operating Activities 92.274 -24.169 -51.723 -71.015 -87.386 -10.853
Cash From Operating Activities 0.64 1.435 2.354 5.317 8.777 8.981
Non-Cash Items 0.169 0.593 2.467 18.902 14.857 -8.816
Changes in Working Capital 99.716 -5.095 -10.507 -2.357 -2.014 19.584
Cash From Investing Activities -2.075 -5.515 -15.663 -24.666 -5.031 -5.803
Capital Expenditures -2.075 -5.565 -15.678 -24.666 -5.031 -5.803
Other Investing Cash Flow Items, Total 0 0.05 0.015 0
Cash From Financing Activities -12.376 -0.937 107.777 173.374 1.329 70.521
Total Cash Dividends Paid -12.425 0
Issuance (Retirement) of Stock, Net 0.049 -0.937 109.913 136.446 0.689 67.26
Net Change in Cash 77.823 -30.621 40.391 77.693 -91.088 53.865
Financing Cash Flow Items -2.136 -2.622 0.64 0.791
Issuance (Retirement) of Debt, Net 39.55 0 2.47
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -18.689 2.967 -8.312 -30.602 -28.168
Cash From Operating Activities 68.072 36.733 12.828 -10.853 -28.872
Cash From Operating Activities 2.176 4.542 6.806 8.981 1.968
Non-Cash Items 3.945 8.158 -5.127 -8.816 5.571
Changes in Working Capital 80.64 21.066 19.461 19.584 -8.243
Cash From Investing Activities -1.125 -2.815 -4.298 -5.803 -0.818
Capital Expenditures -1.125 -2.815 -4.298 -5.803 -0.818
Cash From Financing Activities 36.715 50.227 62.143 70.521 2.249
Financing Cash Flow Items 0.418 0.405 0.791 0.791 0.282
Issuance (Retirement) of Stock, Net 36.297 47.352 58.887 67.26 1.967
Net Change in Cash 103.662 84.145 70.673 53.865 -27.441
Issuance (Retirement) of Debt, Net 2.47 2.465 2.47

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Precision BioSciences, Inc. Company profile

About Precision BioSciences Inc

Precision BioSciences, Inc is a clinical stage biotechnology company. The Company’s ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. The Company’s pipeline includes Ex vivo Allogeneic CAR T Immunotherapy and In vivo Gene Correction. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. The Company’s subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Precision BioSciences Inc revenues increased from $24.3M to $115.5M. Net loss decreased 72% to $30.6M. Revenues reflect Therapeutics segment increase from $21.9M to $111.7M, Food segment increase of 57% to $3.8M. Lower net loss reflects Therapeutics segment income totaling $32M vs. loss of $50M, Food segment loss decrease of 26% to $3.8M.

Industry: Biotechnology & Medical Research (NEC)

302 E Pettigrew St Ste A100
DURHAM
NORTH CAROLINA 27701-2393
US

Income Statement

People also watch

US100

11,990.70 Price
-0.520% 1D Chg, %
Long position overnight fee -0.0166%
Short position overnight fee 0.0059%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.39 Price
-5.260% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00325

Natural Gas

6.72 Price
-3.350% 1D Chg, %
Long position overnight fee 0.0425%
Short position overnight fee -0.0673%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

16,948.85 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading